Literature DB >> 18587441

Future innovations in anti-platelet therapies.

N E Barrett1, L Holbrook, S Jones, W J Kaiser, L A Moraes, R Rana, T Sage, R G Stanley, K L Tucker, B Wright, J M Gibbins.   

Abstract

Platelets have long been recognized to be of central importance in haemostasis, but their participation in pathological conditions such as thrombosis, atherosclerosis and inflammation is now also well established. The platelet has therefore become a key target in therapies to combat cardiovascular disease. Anti-platelet therapies are used widely, but current approaches lack efficacy in a proportion of patients, and are associated with side effects including problem bleeding. In the last decade, substantial progress has been made in understanding the regulation of platelet function, including the characterization of new ligands, platelet-specific receptors and cell signalling pathways. It is anticipated this progress will impact positively on the future innovations towards more effective and safer anti-platelet agents. In this review, the mechanisms of platelet regulation and current anti-platelet therapies are introduced, and strong, and some more speculative, potential candidate target molecules for future anti-platelet drug development are discussed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18587441      PMCID: PMC2451055          DOI: 10.1038/bjp.2008.151

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  268 in total

1.  Plasma fibronectin supports neuronal survival and reduces brain injury following transient focal cerebral ischemia but is not essential for skin-wound healing and hemostasis.

Authors:  T Sakai; K J Johnson; M Murozono; K Sakai; M A Magnuson; T Wieloch; T Cronberg; A Isshiki; H P Erickson; R Fässler
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

2.  Collagen, convulxin, and thrombin stimulate aggregation-independent tyrosine phosphorylation of CD31 in platelets. Evidence for the involvement of Src family kinases.

Authors:  M Cicmil; J M Thomas; T Sage; F A Barry; M Leduc; C Bon; J M Gibbins
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

3.  Arachidonic acid stimulates the formation of 1,2-diacylglycerol and phosphatidic acid in human platelets. Degree of phospholipase C activation correlates with protein phosphorylation, platelet shape change, serotonin release, and aggregation.

Authors:  W Siess; F L Siegel; E G Lapetina
Journal:  J Biol Chem       Date:  1983-09-25       Impact factor: 5.157

Review 4.  Allosteric disulfide bonds in thrombosis and thrombolysis.

Authors:  V M Chen; P J Hogg
Journal:  J Thromb Haemost       Date:  2006-09-26       Impact factor: 5.824

5.  Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange.

Authors:  Judith Lahav; Kerstin Jurk; Oded Hess; Michael J Barnes; Richard W Farndale; Jacob Luboshitz; Beate E Kehrel
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

Review 6.  Platelets in atherothrombosis: lessons from mouse models.

Authors:  B Nieswandt; B Aktas; A Moers; U J H Sachs
Journal:  J Thromb Haemost       Date:  2005-08       Impact factor: 5.824

Review 7.  The role of thiols and disulfides in platelet function.

Authors:  David W Essex
Journal:  Antioxid Redox Signal       Date:  2004-08       Impact factor: 8.401

8.  Class 3 semaphorins control vascular morphogenesis by inhibiting integrin function.

Authors:  Guido Serini; Donatella Valdembri; Sara Zanivan; Giulia Morterra; Constanze Burkhardt; Francesca Caccavari; Luca Zammataro; Luca Primo; Luca Tamagnone; Malcolm Logan; Marc Tessier-Lavigne; Masahiko Taniguchi; Andreas W Püschel; Federico Bussolino
Journal:  Nature       Date:  2003-07-24       Impact factor: 49.962

9.  The neutrophil-specific antigen CD177 is a counter-receptor for platelet endothelial cell adhesion molecule-1 (CD31).

Authors:  Ulrich J H Sachs; Cornelia L Andrei-Selmer; Amudhan Maniar; Timo Weiss; Cathy Paddock; Valeria V Orlova; Eun Young Choi; Peter J Newman; Klaus T Preissner; Triantafyllos Chavakis; Sentot Santoso
Journal:  J Biol Chem       Date:  2007-06-19       Impact factor: 5.157

10.  Long-term antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice.

Authors:  B Nieswandt; V Schulte; W Bergmeier; R Mokhtari-Nejad; K Rackebrandt; J P Cazenave; P Ohlmann; C Gachet; H Zirngibl
Journal:  J Exp Med       Date:  2001-02-19       Impact factor: 14.307

View more
  45 in total

Review 1.  Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases.

Authors:  Jolanta M Siller-Matula; Julia Krumphuber; Bernd Jilma
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

2.  Aged garlic extract suppresses platelet aggregation by changing the functional property of platelets.

Authors:  Naoaki Morihara; Atsuko Hino
Journal:  J Nat Med       Date:  2016-10-20       Impact factor: 2.343

3.  Lysyl oxidase is associated with increased thrombosis and platelet reactivity.

Authors:  Shinobu Matsuura; Rongjuan Mi; Milka Koupenova; Alexia Eliades; Shenia Patterson; Paul Toselli; Jonathan Thon; Joseph E Italiano; Philip C Trackman; Nikolaos Papadantonakis; Katya Ravid
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

4.  Ginsenoside-Rp1 inhibits platelet activation and thrombus formation via impaired glycoprotein VI signalling pathway, tyrosine phosphorylation and MAPK activation.

Authors:  M Endale; W M Lee; S M Kamruzzaman; S D Kim; J Y Park; M H Park; T Y Park; H J Park; J Y Cho; M H Rhee
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

5.  Sulfasalazine and its metabolites inhibit platelet function in patients with inflammatory arthritis.

Authors:  Paul A MacMullan; Anne M Madigan; Nevin Paul; Aaron J Peace; Ahmed Alagha; Kevin B Nolan; Geraldine M McCarthy; Dermot Kenny
Journal:  Clin Rheumatol       Date:  2014-09-26       Impact factor: 2.980

Review 6.  Insights into dietary flavonoids as molecular templates for the design of anti-platelet drugs.

Authors:  Bernice Wright; Jeremy P E Spencer; Julie A Lovegrove; Jonathan M Gibbins
Journal:  Cardiovasc Res       Date:  2012-09-27       Impact factor: 10.787

7.  Simulation of the microscopic process during initiation of stent thrombosis.

Authors:  Jennifer K W Chesnutt; Hai-Chao Han
Journal:  Comput Biol Med       Date:  2014-11-15       Impact factor: 4.589

8.  Beneficial effect of anti-platelet therapies on atherosclerotic lesion formation assessed by phase-contrast X-ray CT imaging.

Authors:  Masafumi Takeda; Tomoya Yamashita; Masakazu Shinohara; Naoto Sasaki; Hideto Tawa; Kenji Nakajima; Atsushi Momose; Ken-Ichi Hirata
Journal:  Int J Cardiovasc Imaging       Date:  2011-06-19       Impact factor: 2.357

9.  Effects of thienopyridines and thienopyrimidinones on L-type calcium current in isolated cardiomyocytes.

Authors:  Brigitte Pelzmann; Klaus Zorn-Pauly; Seth Hallström; Heinrich Mächler; Andrzej Jakubowski; Petra Lang; Bernd Koidl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-09-14       Impact factor: 3.000

Review 10.  Platelet receptors and signaling in the dynamics of thrombus formation.

Authors:  José Rivera; María Luisa Lozano; Leyre Navarro-Núñez; Vicente Vicente
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.